Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension.

ABSTRACT:

Background

Donanemab significantly slowed clinical progression in participants with early symptomatic Alzheimer's disease (AD) during the 76-week placebo-controlled period of TRAILBLAZER-ALZ 2.

Methods

Participants who completed the placebo-controlled period were eligible for the 78-week, double-blind, long-term extension (LTE). Early-start participants were randomized to donanemab in the placebo-controlled period. Delayed-start participants (randomized to placebo) started donanemab in the LTE. Participants who met amyloid treatment course completion criteria were switched to placebo. An external control cohort comprised participants from the AD Neuroimaging Initiative (ADNI).

Results

At 3 years, donanemab slowed disease progression on the Clinical Dementia Rating Sca

SUBMITTER: Zimmer JA 

PROVIDER: S-EPMC12869028 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature